The Cornea Research Foundation is participating in a study of collagen cross-linking (CXL) to assess safety and effectiveness. A new clinical research investigation has begun to study the benefits of corneal collagen cross-linking (CXL) in subjects with progressive keratoconus or corneal ectasia after prior refractive surgery.
These studies are designed to assess the safety and effectiveness of CXL for slowing the progression of both of these conditions. Corneal collagen cross-linking is a procedure that involves administering riboflavin and UVA in carefully selected parameters that strengthen the front layers of the cornea (clear covering of the eye) and avoid damage to the back part of the eye. The riboflavin and UVA light source that is used for CXL are both investigational in the United States and are not yet approved by FDA. If you qualify and decide to participate in the study, you will receive the riboflavin and UVA light at no cost. However, there is a fee for the examinations. Because of the investigative nature of the procedure, most insurance companies will not cover the surgery and you will be required to pay this fee up-front before the procedure is performed.
If you, or someone you know, may be interested in participating in this CXL study, please contact Kelly Fairchild to learn more about the study or to schedule a consultation examination to see if you qualify for the study. She may be reached at: 317-814-2995 and by e-mail address at email@example.com . The Foundation’s website is www.cornea.org.